Protein– tag –
-
COVID-19 mRNA Vaccines Comprehensively Proven Safe and Effective, Establishing Foundation for Future mRNA Therapeutics
CIDRAP (Center for Infectious Disease Research and Policy) USA Overview Extensive real-world use and rigorous evaluation of COVID-19 mRNA vaccines have conclusively demonstrated their comprehensive safety and efficacy, establishing a rob... -
Challenges in AI Drug Discovery Clinical Success Rates: Insilico’s Lenticelib First to Phase II, AlphaFold Accelerates Structural Biology
MDPI Switzerland Overview While AI drug discovery accelerates early-stage discovery, consistent improvement in late-stage clinical trial success rates remains a challenge. However, Insilico Medicine's lenticelib (NCT05938920) has become ... -
Patisiran and Inotersen Halt Polyneuropathy Progression in hATTR Amyloidosis; Next-Gen siRNA Vutrisiran Also FDA Approved
oneAMYLOIDOSISvoice USA Overview Patisiran (Onpattro) and inotersen (Tegsedi), TTR mRNA silencing therapies for hereditary ATTR amyloidosis (hATTR), have demonstrated the ability to halt the progression of polyneuropathy and even show im... -
AI Significantly Reduces Drug Discovery Space: De Novo Protein Design and Bruker’s Data Platform Accelerate Innovation
Temple 8 Unknown Overview AI models are drastically reducing the biological exploration space in drug discovery by screening billions of virtual molecules in seconds, predicting binding affinities, and optimizing pharmacokinetic properti... -
Exponential Progression of Targeted Protein Degradation: First FDA-Approved PROTAC and Molecular Glues Unlock “Undruggable” Targets
MarinBio (Appears to be a scientific review/journal, affiliated with MarinBio, hence using their domain) USA Overview The field of targeted protein degradation (TPD) is rapidly evolving, enabling the degradation of previously "undruggabl... -
AI-Designed Drugs from DeepMind’s AlphaFold, Insilico, and Generate Biomedicines Advance to Mid-Late Stage Clinical Trials, Intensifying Drug Discovery Race
MedCity News USA Overview The AI drug discovery sector is intensifying as advanced AI-designed drugs are poised to deliver mid-to-late stage clinical trial results within the next two years, leveraging breakthroughs like DeepMind's Alpha... -
Arvinas/Pfizer’s PROTAC Drug Veppanu Receives Historic FDA Approval for ESR1-Mutant Advanced Breast Cancer, Demonstrating 43% PFS Risk Reduction
Cancer Discovery - AACR Journals USA Overview Arvinas and Pfizer's oral PROTAC drug, Veppanu, has received FDA approval for advanced breast cancer with ESR1 mutations, marking the first clinical validation of targeted protein degradation... -
Ionis Enters Global Licensing Deal with Recordati for Alexander Disease ASO Zilganersen: Secures $30M Upfront Payment to Accelerate International Expansion
Rare Disease Report USA Overview Ionis Pharmaceuticals has entered a global licensing agreement with Recordati for zilganersen, an antisense oligonucleotide (ASO) for Alexander disease, covering territories outside the U.S. Ionis will re... -
Focused Ultrasound BBB Opening Facilitates Limited LNP-modRNA Brain Delivery in Niemann-Pick Disease Type C Mouse Model but Fails to Induce Therapeutic Effect
bioRxiv Unknown Overview Efficient molecular therapeutic delivery to the central nervous system (CNS) remains a major barrier in neurogenetic disorders like Niemann-Pick Disease Type C (NPC). This preprint evaluated Focused ultrasound-me... -
EAACI 2026: Wave Life Sciences’ siRNA BW-20805 Shows 93-99% Attack Rate Reduction in Hereditary Angioedema Phase 2, with 60-83% Patients Remaining Attack-Free
EMJ Allergy & Immunology Unknown Overview At the EAACI 2026 conference, updated Phase 2 data for Wave Life Sciences' BW-20805, a plasma prekallikrein-targeting GalNAc-siRNA, revealed highly promising results in adult patients with heredi...
